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Abstract
Background: Platelets have been proven to be a useful cellular model to study some neuropathologies, due to the
overlapping biological features between neurons and platelets as granule secreting cells. Altered platelet dense
granule morphology was previously reported in three autism spectrum disorder (ASD) patients with chromosomal
translocations that disrupted ASD candidate genes NBEA, SCAMP5, and AMYSIN, but a systematic analysis of platelet
function in ASD is lacking in contrast to numerous reports of elevated serotonin levels in platelets and blood as
potential biomarker for ASD.
Methods: We explored platelet count, size, epinephrine-induced activation, and dense granule ATP secretion in a
cohort of 159 ASD patients, their 289 first-degree relatives (103 unaffected siblings, 99 mothers, and 87 fathers), 45
adult controls, and 65 pediatric controls. For each of the responses separately, a linear mixed model with gender as
a covariate was used to compare the level between groups. We next investigated the correlation between platelet
function outcomes and severity of impairments in social behavior (social responsiveness score (SRS)).
Results: The average platelet count was increased in ASD patients and siblings vs. controls (ASD 320.3 × 109/L,
p = 0.003; siblings 332.0 × 109/L, p < 0.001; controls 283.0 × 109/L). The maximal platelet secretion-dependent
aggregation response to epinephrine was not significantly lower for ASD patients. However, secondary wave
responses following stimulation with epinephrine were more frequently delayed or absent compared to controls
(ASD 52 %, siblings 45 %, parents 53 %, controls 22 %, p = 0.002). In addition, stimulated release of ATP from dense
granules was reduced in ASD patients, siblings, and parents vs. controls following activation of platelets with either
collagen (ASD 1.54 μM, p = 0.001; siblings 1.51 μM, p < 0.001; parents 1.67 μM, p = 0.021; controls 2.03 μM) or ADP
(ASD 0.96 μM, p = 0.003; siblings 1.00 μM, p = 0.012; parents 1.17 μM, p = 0.21; controls 1.40 μM). Plasma serotonin
levels were increased for ASD patients (n = 20, p = 0.005) and siblings (n = 20, p = 0.0001) vs. controls (n = 16). No
significant correlations were found in the different groups between SRS scores and count, size, epinephrine
aggregation, or ATP release.
Conclusions: We report increased platelet counts, decreased platelet ATP dense granule secretion, and increased
serotonin plasma levels not only in ASD patients but also in their first-degree relatives. This suggests that potential
genetic factors associated with platelet counts and granule secretion can be associated with, but are not fully
penetrant for ASD.
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Background
Autism spectrum disorders (ASDs) are a heterogeneous
group of neurodevelopmental disorders characterized by
impairments in reciprocal social interactions, verbal and
non-verbal communication, and stereotyped behavior.
The prevalence of ASD is estimated to be around 1.5 %
of the population and has risen rapidly the past decade
making it now one of the most prevalent disorders in
childhood [1]. Although ASD is a highly heritable dis-
order [2], the genetic cause is complex and involves a
multitude of genes, genetic heterogeneity, imprinting as
well as gene-environment interactions [3–5]. Gene path-
way analysis studies have provided insight in the diverse
nature of the genetic abnormalities, and it now becomes
evident that the majority of genetic defects influence a
limited number of core functional mechanisms in the
brain [6–10]. These identified networks are mainly re-
lated to the neuronal synapse and include synaptic plas-
ticity, structure, signaling, and transcriptional regulation.
Studying synaptic function in vivo and modeling the
effect of single gene mutations in vitro are challenging
despite the availability of non-invasive technologies to
study human brain function and the development of
several animal models [11–13].
Blood platelets and neurons that seem to share some
typical characteristics as subclinical platelet abnormal-
ities were often detected in monogenetic and complex
neurological diseases [14, 15]. Detailed functional plate-
let testing was performed to gain insights in the disease
mechanisms of some monogenetic neuropathologies by
elucidating abnormalities in transcription factors, mem-
brane transporters, G-protein signal transduction, and
cytoskeletal proteins (e.g., Rett syndrome [16], intellec-
tual disability, and others [17–19]). However, in the early
1970s, studies focused mainly only on the overlapping
serotonin metabolism in neurons and platelets [20, 21],
both comprising the active transport system for sero-
tonin [22], storage into specialized dense core granules,
and availability of monoamine oxidase in mitochondria.
Since then, additional research has shown that both neu-
rons and platelets contain overlapping gene expression
profiles, similar types of granules loaded with partially
the same signaling molecules such as ATP and sero-
tonin, and that both cell types use Ca2+, intracellular in-
ositol phosphate and the prostaglandin pathway as
initiators of granule secretion. Moreover, the highly spe-
cialized process of regulated granule trafficking and se-
cretion found in neurons mirrors at least partially that of
platelets [23, 24]. Abnormalities in the platelet serotonin
metabolism have been described in different complex
neurological diseases, including schizophrenia [25], mi-
graine [26], and Alzheimer’s disease [27]. Elevated blood
serotonin level is also the first quantitative trait found to
be associated with ASD [28, 29]. A familial study showed
that plasma free serotonin is correlated with ASD but is
not different between ASD cases and their siblings or
parents [30]. This study also pointed out that the differ-
ence in serotonin is due only to the serotonin of the
platelet fraction as the association was not found for
serotonin levels in platelet-poor plasma. A study by
Piven J et al. showed that serotonin levels in platelet-rich
plasma of ASD patients with affected siblings were sig-
nificantly higher than probands without affected siblings,
though, the latter cases still had serotonin levels signifi-
cantly higher than controls [31]. A recent meta-analysis
of all literature studies reporting ASD and control blood
serotonin values concluded that elevated serotonin levels
were recorded in 28.3 % in whole blood and 22.5 % in
platelet-rich plasma samples of ASD patients, as re-
ported in 15 and 4 studies, respectively, using different
detection techniques [32]. It is difficult to make an overall
conclusion concerning the true association between ASD
and serotonin as potential biomarker since serotonin con-
centrations are highly dynamic in the central nervous
system and around [33], and different methods to measure
serotonin using different biomaterials (whole blood, plate-
lets, platelet-rich, or platelet-poor plasma) do exist [34].
This, altogether, probably accounts for the differences
amongst a large number of studies that report serotonin
levels as being a possible true biomarker for ASD or not.
Platelets store and release upon activation of serotonin
from their dense granules and therefore, we hypothe-
sized that differences in the platelet serotonin metabol-
ism can be due to abnormalities in platelet dense
granule formation, transport, and secretion. Therefore, it
is also important to study the morphology and release of
the platelet dense granules in addition to measuring
serotonin levels. Indeed, we previously observed an al-
tered platelet dense granule morphology in three unre-
lated ASD patients with chromosomal translocations. It
was shown that the identified ASD candidate genes
NBEA, SCAMP5, and AMISYN involved in these trans-
locations play a role in stimulated secretion of large
dense-core vesicles [35, 36]. Interestingly, heterozygous
NBEA-deficient mice also have autistic-like behavior
problems [37] and a platelet dense granule morphology
defect but these mice have normal serotonin levels in
platelets and serum [38]. Therefore, we hypothesized
that in at least a subgroup of ASD patients, a defect in
synaptic neuronal signaling would be reflected by alter-
ations in platelet dense granule secretion. Platelets offer
a unique opportunity to assess the stimulated dense
granule function, in a relatively noninvasive and high-
throughput manner because they can be isolated from
peripheral blood in a non-active state. We here evalu-
ated platelet count, size, and activation in addition to the
classic measurements of only plasma serotonin levels in
a non-syndromic familial ASD cohort.
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Methods
Study participants and clinical evaluations
Written informed consent was obtained for all studies
from all participants and/or their legal representatives.
The Medical Ethical Committee of the University Hospi-
tals of Leuven approved this study (project number
S50717). Participants from the larger ASD family cohort
recruited by the Leuven Autism Research (LAuRes) con-
sortium that were previously described [39] were asked
to participate additionally in this platelet study. A total
(n = 448) of 159 ASD patients and 289 first-degree rela-
tives (103 unaffected siblings and 186 parents) from the
LAuRes cohort agreed to enroll in this study. Further
characteristics of the ASD family and unrelated healthy
adult and pediatric control cohorts are presented in
Table 1. Briefly, the diagnosis ASD was made in children
by multidisciplinary teams in a standardized way accord-
ing to DSM-IV-TR criteria [40]. Parents were asked to
fill out the developmental, dimensional and diagnostic
interview (3di) [41] and social responsiveness scale (SRS)
[42] about their children under 18 years old. We also
asked them to have an adult SRS filled out about them-
selves by their partner. We included only children under
18 years of age and excluded half-siblings. Besides obtain-
ing the adult SRS scores, parents were not additionally
screened for ASD but five fathers were previously
diagnosed with ASD and were excluded from the analysis
of this study. Individuals who used platelet function-
interfering medication preceding blood drawing were also
excluded from the study (Additional file 1: Table S1). The
adult control cohort for the platelet functional tests
included 45 unrelated adults from the general population
that specifically consented for functional platelet testing.
Since the platelet counts and mean platelet volume
(MPV) are age dependent, we also included data from a
pediatric control cohort (n = 65) that was previously
recruited for a different study (obesity medication, blood
sampling before onset of the study) to compare these
parameters. Written informed consent from these partici-
pants was given for the use of platelet count and size in
research context. The ATP secretion and aggregation
studies were not included in the pediatric study and
therefor not available. Unfortunately, these adult and
pediatric control cohorts were only assumed to be non-
ASD cases but they were not specifically tested using the
DSM-IV-TR or SRS systems. We recorded no data related
to cardiovascular risk factors (smoking, hypertension,
weight, etc.) for any of the participants.
Platelet count, size, and functional platelet studies
Blood (40 mL) from each individual was anti-coagulated
with 129 mmol/L trisodium citrate (9:1) and used within
2 h to obtain platelet-rich plasma (PRP). Hemolytic or
lipemic samples were excluded for further studies
(Additional file 1: Table S1). Platelet count in the
PRP was adjusted to 250 × 109 platelets/L. The PRP
was used for functional platelet studies as described
[17, 18, 43]. Briefly, aggregation studies were performed
on two dual-channel Chrono-Log aggregometers (Chron-
olog, Havertown, PA, USA) by adding 1.25 μg/mL epi-
nephrine, 2.5 μg/mL epinephrine or 1 mM arachidonic
acid (AA; Sigma Chemical Co, St Louis, MO). The max-
imal aggregation response (amplitude, %) and the rate of
aggregation (slope) are automatically measured and re-
ported by the aggregometer. Platelet secretion was deter-
mined by measuring the release of adenosine-triphosphate
(ATP) using luciferin/luciferase reagent (Kordia, Leiden,
the Netherlands) after stimulation with 10 μM adenosine-
diphosphate (ADP; Sigma Chemical) or 1 mg/mL Horm
collagen (Nycomed Arzenmittel, Munich, Germany).
Though all participants were questioned in detail for medi-
cation use to exclude potential drug-interfering effects on
platelet activation, the AA-induced aggregation response
was performed to exclude potential side effects of aspirin
or other nonsteroidal anti-inflammatory drugs (NSAIDs)-
like drugs that typically interfere with AA responses.
Whole blood cell counts were obtained with an auto-
mated cell counter (Cell-Dyn 1300; Abbott Laboratories,
Abott Park, IL, USA) using EDTA-treated blood samples
for all individuals except for the adult controls for which
no EDTA-treated samples were collected. Serotonin was
measured in platelet-poor plasma (from EDTA-treated
blood samples) in a smaller group of age and gender-
matched ASD children (n = 30, age M = 14 range 9–18),
Table 1 Demographics of the study participants
ASD family cohorts Control cohorts
ASD Siblings Parents Pediatric Adult
N 159 103 186 65 45
Gender (male-female) 125–34 34–69 87–99 31–34 22–23
Age (years) 11.9 ± 3.8 13.0 ± 4.7 43.0 ± 4.4 15.6 ± 3.9 36.5 ± 10.9
Intellectual disability (%) 18 (11) 1 (1) 0 (0) 0 (0) 0 (0)
SRS score 89.6 ± 16.5 (3) 50.0 ± 9.7 (3) 48.0 ± 8.7 (15) nd nd
Data are expressed as mean ± standard deviation (missing values) or n (%)
ID intellectual disability is defined as IQ < 70, SRS social responsive scale, nd not determined
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non-ASD siblings (n = 30, age M = 14 range 9–18), and
pediatric controls from whom samples were available
(n = 16, age M = 14 range 9–20) using a competitive
ELISA according to the manufacturers instructions
(IBL International, Hamburg, Germany). C-reactive
protein (CRP) levels were measured in citrated plasma
samples from the same subjects as mentioned for the
serotonin measurements using the human (CRP) Quanti-
kine ELISA kit according to the instructions (R & D
Systems inc, Minneapolis, MN).
Statistical analysis
Spearman correlations, Fisher’s exact, and Mann-Whitney
U tests were used for exploratory purposes. For each of
the responses (platelet count, mean platelet volume, ag-
gregations, and ATP secretions) separately, a linear mixed
model was used to compare the level between children
with ASD, siblings, parents, and either children or adult
controls. The included random effects in the mixed
models imposed restrictions on the covariance matrix of
the responses predicated by genetic theory. More specific-
ally, they refer to an additive genetic component and a
common environmental component [44] to account for
the fact that ASD children and siblings are raised in the
same family setting. Gender was added as covariate in the
mixed model analysis. In the correlation analysis, children
with ASD, siblings, and parents are compared with gender
and the SRS score as covariates. Tukey’s adjustments for
multiple testing are used for the pairwise comparisons
between groups in all analyses. The residual variability of
the responses is allowed to be group-specific. p values
smaller than 0.05 are considered significant. All analyses
have been performed using SAS software, version 9.2 of
the SAS System for Windows.
Results
Platelet count and size in ASD family and pediatric
control cohorts
Platelet count and size as represented by the mean plate-
let volume (MPV) were assessed in individuals with
ASD, their first-degree relatives and pediatric controls
(Table 1 for cohort characteristics). ASD patients and
their siblings have higher platelet counts compared to
age-matched pediatric controls (Table 2). Within the
ASD family subgroups, total platelet count did not differ
between genders, except for the parent sample where the
mean platelet count was higher for mothers (M = 308, SD
6.4) compared to fathers (M = 290, SD 6.1, p = 0.04). A
linear mixed model showed a significant effect of group
on platelet count (p < 0.001). Post-hoc pairwise tests re-
vealed significant differences between ASD patients and
non-ASD siblings compared to parents and pediatric con-
trols, but not between ASD patients and their unaffected
siblings (Fig. 1a). Furthermore, we observed mild throm-
bocytosis (platelet counts above the normal upper limit of
450 × 109/L blood) in several ASD patients, siblings, and
parents (Table 2).
Whole blood measurements in normal human subjects
always reveal an inverse relation between platelet count
and MPV [45, 46]. This inverse relationship was also
found for ASD patients (N = 157, rho = −0.48, r2 = 0.23,
p < 0.001). As therefore expected, the MPV was de-
creased for both ASD patients and siblings compared to
the pediatric control group (Table 2). However, linear
mixed model analysis showed no significant differences
in MPV amongst the groups (Fig. 1b).
Platelet activation studies in ASD family and adult
control cohorts
Agonist-induced platelet activation was assessed in ASD
family and adult control cohorts using the in vitro aggre-
gation test. Platelet activation studies with arachidonic
acid (AA) being the precursor of thromboxane A2
(TxA2), a strong stimulator of platelet activation, were
mainly included to control for medication-interfering
drugs (such as NSAIDs) that typically affects the AA-in-
duced platelet aggregation (AA-induced platelet activation
pathway shown in red in Additional file 2: Figure S1). No
significant difference in the maximal AA-induced
aggregation amplitude was observed between the different
ASD family subgroups or the control cohort (Additional
file 2: Figure S2).
We next assessed the platelet activation response to
the granule secretion-dependent platelet activating agon-
ist epinephrine. Epinephrine is a weak agonist that
induces the release of intracellular calcium leading to a
Table 2 Platelet count and size in ASD family cohorts and pediatric controls
ASD Siblings Parents Pediatric controls
N 158a 103 186 65
Platelet count (×109/L blood) 318.7 ± 71.9 337.2 ± 67.6 300.6 ± 62.0 283.4 ± 67.2
Thrombocytosis 6 (3.8) 4 (4.0) 4 (2.1) 0 (0)
MPV (fL) 8.2 ± 1.0 (1) 8.3 ± 1.1 8.5 ± 1.1 8.8 ± 1.2
Data are expressed as mean ± standard deviation (missing values) or n (%). Values are represented as unadjusted raw values. Thrombocytosis is defined by a
platelet count >450 × 109/L. Platelet size is indicated with mean platelet volume (MPV)
aAn EDTA blood sample was missing from one ASD patient from which platelet count and MPV could therefore not be measured. A MPV measurement for a
second ASD patient was missing due to sampling failure of the counter
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“primary wave” of aggregation. This initial aggregation
response can be followed by a “secondary wave” if TxA2,
ADP, and other stimulatory molecules are released from
the platelet granules to amplify the primary aggregation
response (illustrated in Fig. 2a and pathway shown in
blue in Additional file 2: Figure S1). The maximal ampli-
tude for the epinephrine-induced platelet aggregation is
therefore determined by both waves. Using the linear
mixed model analysis, no significant different in max-
imal amplitude was measured in stimulated platelets
from ASD patients, non-ASD siblings, parents, and adult
controls using either intermediate (2.5 μg/mL) or low
(1.25 μg/mL) concentrations of epinephrine (Fig. 2b, c).
Though not significant, a trend for lower maximal
aggregation amplitudes was observed after stimulation
with 1.25 μg/mL epinephrine in all ASD family sub-
groups when compared with the adult control cohort.
Since the maximal amplitude is a combination between
primary and secondary aggregation responses, we also
directly scored the secretion-dependent secondary wave
as being present, delayed, or absent (as illustrated in
Fig. 2a). Interestingly, for the adult control cohort, only
16 % of all participants showed a delayed or absent sec-
ondary wave towards 2.5 μg/mL epinephrine stimulation
compared to 39, 30, and 42 % in the ASD, non-ASD sib-
ling, and parent groups, respectively (p = 0.002) (Fig. 2d).
This secondary wave scoring difference was even more
pronounced for stimulations with the low dose of
epinephrine (ASD 52 %, siblings 45 %, parents 53 %,
controls 22 %, p = 0.002 (Fig. 2e)). However, no scoring
differences were observed between ASD and non-ASD
participants within the family cohort.
Platelet dense granule ATP secretion in ASD family and
adult control cohorts
As ASD family participants have a delayed or absent gran-
ule secretion-dependent secondary wave after stimulation
with epinephrine, abnormal platelet dense granule secre-
tion would further support this finding. Platelet stimulation
results in the fusion of granules with plasma membranes
to release their content [47]. We measured the release of
ATP stored in dense granules after platelet stimulation
with the different agonist collagen and ADP in platelet-rich
plasma from ASD family and control cohort participants
(secretion pathway induced by ADP and collagen is
illustrated in Additional file 2: Figure S1). Collagen is a
strong agonist that induces platelet aggregation and TxA2
synthesis with simultaneous platelet granule secretion.
Using a dose of 2 μg/mL collagen, we found that ATP
release was significantly lower in the ASD, non-ASD
sibling, and parent groups compared to controls but also
amongst the ASD and sibling group vs. the parents, as de-
termined in the linear mixed model analysis (Fig. 3a). ADP
is a weak agonist that is also stored in the dense granules
of platelets. Full granule secretion after ADP stimulation
can only occur in response to a positive feedback loop fol-
lowing platelet aggregation and TxA2 synthesis. Following
activation with 10 μM ADP, ATP release was significantly
lower in the ASD patients and siblings but not in parents
compared to controls using linear mixed model analysis
(Fig. 3b). Significant differences were also observed be-
tween ASD patients compared to parents, but not between
ASD patients and their non-ASD siblings.
Plasma serotonin levels in ASD family and pediatric
control cohorts
Regulation of plasma serotonin levels involves the activ-
ity and presence of the serotonin transporter at the
plasma membrane of platelets. In addition, platelets ex-
press the G protein-coupled serotonin receptor that by
itself cannot trigger platelet aggregation but can partici-
pate with other platelet agonists to obtain full platelet
aggregation. High serotonin levels in plasma can therefore
a
b
Fig. 1 Platelet count and size in ASD patients, siblings, parents, and
pediatric controls. Graphs indicating gender-corrected least squares
means and 95 % CI values based on the linear mixed model analysis
of platelet count (a) and platelet size (b) in 159 ASD patients, 103
siblings, 186 parents, and 65 pediatric controls measured in whole
blood. Tukey-Kramer-adjusted p values of the pairwise comparisons
in four groups are indicated when they are significant (p < 0.05)
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result in a higher sensitivity towards weak agonists such as
ADP and epinephrine. We measured serotonin levels in
randomly selected subgroup of ASD patients and siblings
and found elevated plasma serotonin compared to con-
trols (Fig. 4a). Again, no difference was observed between
ASD and non-ASD siblings. Therefore, the increased sen-
sitivity of control platelets to epinephrine or ADP stimula-
tion cannot be attributed to higher serotonin plasma
levels. In addition, as it is known that platelet activity is
sensitive to the inflammation status of the blood [48], we
also determined C-reactive protein (CRP) levels in the
plasma samples from the same group of patients, siblings,
and controls but found no significant differences between
the groups (Fig. 4b).
Clinical correlates of platelet function and counts
Given the association between platelet count and func-
tion changes and the presence of ASD in the family, we
a
b c
d e
Fig. 2 Aggregation responses following platelet activation with epinephrine in ASD patients, siblings, parents, and adult controls. a Schematic
representation of platelet aggregation curve induced by 1.25 μg/mL epinephrine showing monophasic (1 wave), biphasic (2 waves), or delayed
biphasic aggregation curves. Graphs indicating gender-corrected least squares means and 95 % CI values based on the linear mixed model
analysis of maximal aggregation amplitude in response to b 2.5 μg/mL epinephrine and c 1.25 μg/mL epinephrine measured in 159 ASD patients,
103 siblings, 186 parents, and 45 adult controls measured in platelet-rich plasma. Tukey-Kramer-adjusted p values of the pairwise comparisons in
four groups are indicated when they are significant (p < 0.05). Graphs indicating percentage of individuals per group with either normal, delayed,
or absent secondary wave aggregation following d 2.5 μg/mL epinephrine, or e 1.25 μg/mL epinephrine
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explored the possibility that these parameters could cor-
relate with autism traits within the families. We therefore
evaluated the association of platelet counts, aggregation,
ATP secretion, and serotonin levels with SRS scores of
ASD patients, siblings, and parents. Interestingly, we
found small but significant correlations between SRS
scores and mean platelet volume (r = −0.11, p = 0.02), ag-
gregation with 2.5 μg/mL epinephrine (r = −0.12, p = 0.01),
ATP release with collagen (r = −0.11, p = 0.02), and ATP
release with ADP (r = −0.13, p = 0.01). These correlations
lost significance when assessed for the individual groups
within the ASD family cohort probably because of the
small sample sizes.
Discussion
Platelet function studies in non-syndromic ASD families
revealed abnormalities in platelet count, epinephrine-
induced secondary wave aggregation responses, and
dense granule ATP secretion not only in ASD patients
but also in their first-degree relatives, namely their par-
ents and non-ASD siblings. A weakness of our study is
that we have only used adult controls for functional
platelet studies and pediatric controls for platelet count
and volume measurements. In addition, we could not
test these control cohorts for ASD features. All analyses
were controlled for a gender effect. We analyzed the
effect of age on our studied parameters and found a
significant effect within the children group for platelet
counts only. This might be caused by an effect of pu-
berty, as the number of post-puberty in the ASD group
is lower than that in the siblings (15 % for ASD vs 23 %
for siblings). However, the small group size made it im-
possible to distinguish between these age groups by lack
of statistical power.
The observed platelet functional abnormalities in ASD
cases and their non-affected siblings are typically related
to a defect in dense granules as we have found before in
some ASD patients with chromosomal abnormalities
[35]. This type of platelet defect is mild and is not ex-
pected to result in obvious clinical bleeding problems.
The functional platelet test as performed in the current
study cannot be used for diagnosis or even for prognosis
of ASD as this type of defect is not specific for ASD.
Mild dense granule secretion defects were previously
also found for patients with a monogenetic neuropathol-
ogy [16, 17]. However, we believe that the study is im-
portant as a subgroup of ASD patients and first-degree
relatives are identified with an obvious platelet dense
granule secretion defect, and this population will further
be investigated by more specific platelet tests that are
not feasible for large scale studies such as morphological
dense granule investigations by electron microscopy and
dense granule formation, transport, and secretion assays
using specific markers in platelets and during megakar-
yopoiesis [49]. In addition, ASD patients with platelet
abnormalities will be selected for further next generation
sequencing studies since important platelet-based tools
are available that will assist candidate gene selection. We
expect that the causative gene is expressed by megakar-
yocytes and detailed gene expression data are now avail-
able for all blood cells [50]. An important set of next
generation sequencing data is available for 707 patients
with bleeding and platelet disorders (BPD) that will be
used as internal control to filter for candidate gene vari-
ants [51]. ASD patients with platelet defects identified in
the current study will now be sequenced and analyzed in
parallel with this large dataset of BPD. Interestingly, the
initial analysis of these 707 BPD patients that did not yet
a
b
Fig. 3 ATP secretion response following platelet activation in ASD
patients, siblings, parents, and adult controls. Graphs indicating
gender-corrected least squares means and 95 % CI values based on
the linear mixed model analysis of ATP release in response to
a collagen and b ADP in 159 ASD patients, 103 siblings, 186
parents, and 45 adult controls measured in platelet-rich plasma.
Tukey-Kramer-adjusted p values of the pairwise comparisons in
four groups are indicated when they are significant (p < 0.05)
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include samples from this familial ASD study showed a
significant association between human phenotype ontol-
ogy terms for the “blood” and “brain” systems.
We realize that the secretion-dependent aggregation
and ATP dense granule secretion abnormalities in chil-
dren with ASD, their siblings and their parents can be
caused by many different genes. There is a plethora of
genes that could cause abnormalities in platelet function,
many of which have been described in the field of bleed-
ing disorders [52]. An altered platelet function without
associated bleeding problems has also been described in
a number of monogenetic and complex neurological dis-
orders [14]. These alterations include changes in MAO
activity, serotonin metabolism, platelet aggregation, and
dense granule secretion in schizophrenia [25], platelet
morphology and MAO metabolism in Parkinson’s dis-
ease [53, 54], and altered platelet serotonin metabolism
in depression [55]. Recently, platelet defects were also
described in idiopathic ASD patients carrying de novo
chromosomal translocations near NBEA, SCAMP5, and
AMYSIN, and in vitro gene silencing studies linked
these genes to a role in vesicle secretion [35]. These im-
portant findings underscore the possibility that single
genetic defects can cause both a neurological phenotype
and a platelet secretion defect.
Platelet counts are kept at constant levels by an ele-
gant feedback mechanism provided by the cytokine
thrombopoietin (TPO), which is produced in liver and
kidneys. Increased levels of TPO induce production of
platelets by megakaryocytes in the bone marrow, and
platelets themselves serve as a clearance sink for TPO
keeping production in balance [56]. To our knowledge,
altered plasma TPO levels have not been documented in
ASD. However, a plausible explanation for the higher
platelet counts might also simply be deduced from our
observation that platelets of ASD patients and family
members are less prone to activation during blood draw-
ing. Their circulating platelets also have reduced tendency
to adhere in vivo to endothelial cells and neutrophils. The
increase in platelet counts in ASD might therefore simply
reflect their relative resting state under basal conditions.
We found no significant change in MPV as previously
reported by others [57].
Consistent with previous reports, serotonin levels were
increased in this cohort of patients with ASD and their
siblings [32]. Physiologically, elevated blood serotonin
levels have been linked to the density of the serotonin
transporter at the plasma membrane of platelets [58].
The regulation of its activity and trafficking involves a
complex of proteins including the αIIbβ3 integrin recep-
tor that is responsible for sustained platelet activation.
Reduced function of this receptor was recently linked to
reduced uptake of serotonin by the serotonin transporter
[59]. Since we find reduced platelet aggregation and se-
cretion in ASD, we hypothesize that the increased sero-
tonin levels are caused by reduced uptake rather than by
increased release from platelets.
Using the linear mixed model that corrects for a com-
mon genetic and environmental background [44], we
could not detect any significant platelet count or func-
tion differences between ASD patients and their non-
ASD siblings. This finding is in accordance with the idea
that development of ASD may involve the interaction
between rare genetic variants with moderate effects in
different genes rather than the addition of Mendelian
inheritance. ASD is a complex polygenetic disease for
which, a cumulative effect of low-penetrance genetic
factors or gene-dosage effect is expected that would have
a b
Fig. 4 Plasma serotonin and CRP levels in ASD patients, siblings, and pediatric controls. a Plasma serotonin levels were measured using an ELISA
in a selection of ASD patients (n = 30), siblings (n = 30), and age-matched controls (n = 16). Line and whiskers indicate mean and SEM. Groups were
compared using the Mann-Whitney U test. b Plasma CRP levels were measured using an ELISA in the same selection of ASD patients (n = 30),
siblings (n = 30), and age-matched controls (n = 16). Line and whiskers indicate mean and SEM. Groups were compared using the Mann-Whitney U test
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partial effects on the platelets of non-ASD siblings and
parents. Further platelet studies in larger cohorts are
needed to study such cumulative effects. Another pos-
sible weakness of this study is that the platelet function
tests in ASD children were compared with adult controls
only. However, platelet function is to our knowledge not
age dependent (unlike platelet count and MPV) but
additional independent studies are needed to confirm
our initial findings.
Conclusions
Though this study was limited by potential confounders
such as cohorts biased and the missing information re-
lated to comorbidities and medications, we have found
evidence for increased platelet counts, and decreased
platelet secretion-dependent aggregation, and ATP dense
granule secretion responses in ASD patients and first-
degree relatives. Specific testing for platelet dense gran-
ule secretion in larger ASD cohorts must be performed
to find out if this test can be used as a detection method
for ASD.
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enzyme COX1 to finally active the G protein-coupled thromboxane receptor
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